MedTrace Logo

Effect of Rivaroxaban on Coagulation Parameters- an ex Vivo Study

NCT00986635 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2011-04-08

No results posted yet for this study

Summary

Rivaroxaban represent a new class of anticoagulation agents. As an oral direct factor Xa inhibitor it has been effective in preventing venous thromboembolism in patients undergoing elective orthopaedic surgery. This ex vivo study is undertaken to investigate the ex-vivo effects of Xarelto® on different coagulation parameters.

Conditions

  • Differences in Laboratory Coagulation Parameters

Sponsors & Collaborators

  • Johann Wolfgang Goethe University Hospital

    lead OTHER

Principal Investigators

  • Helen Mani, PhD · Johann Wolfgang Goethe University Hospital Frankfurt/Main Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-06-30
Completion
2011-04-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00986635 on ClinicalTrials.gov